Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 255

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

Open access
Decaestecker, Karel, De Meerleer, Gert, Lambert, Bieke, Delrue, Louke, Fonteyne, Valérie, Claeys, Tom, De Vos, Filip, Huysse, Wouter, Hautekiet, Arne, Maes, Gaethan, Ost, Piet·2014·Radiation Oncology

Abstract

PURPOSE: To assess the outcome of prostate cancer (PCa) patients diagnosed with oligometastatic disease at recurrence and treated with stereotactic body radiotherapy (SBRT). METHODS: Non-castrate patients with up to 3 synchronous metastases (bone and/or lymph nodes) diagnosed on positron emission tomography - computed tomography, following biochemical recurrence after local curative treatment, were treated with (repeated) SBRT to a dose of 50 Gy in 10 fractions or 30 Gy in 3 fractions. Androgen deprivation therapy-free survival (ADT-FS) defined as the time interval between the first day of SBRT and the initiation of ADT was the primary endpoint. ADT was initiated if more than 3 metastases were detected during follow-up even when patients were still asymptomatic. Secondary endpoints were local control, progression free survival (PFS) and toxicity. Toxicity was scored using the Common Terminology Criteria for Adverse Events. RESULTS: With a median follow-up from time of SBRT of 2 years, we treated 50 patients with 70 metastatic lesions with a local control rate of 100%. The primary involved metastatic sites were lymph nodes (54%), bone (44%), and viscera (2%). The median PFS was 19 mo (95% CI: 13-25 mo) with 75% of recurring patients having ≤3 metastases. A 2nd and 3rd course of SBRT was delivered in 19 and 6 patients respectively. This results in a median ADT-FS of 25 months (20-30 mo). On univariate analysis, only a short PSA doubling time was a significant predictor for both PFS (HR: 0.90, 95% CI: 0.82 - 0.99) and ADT-FS (HR: 0.83; 95% CI: 0.71 - 0.97). Ten patients (20%) developed toxicity following treatment, which was classified as grade I in 7 and grade II in 3 patients. CONCLUSION: Repeated SBRT for oligometastatic prostate cancer postpones palliative androgen deprivation therapy with 2 years without grade III toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1748-717x-9-135

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 255

Metadata

Authors
Decaestecker, K., De Meerleer, G., Lambert, B., Delrue, L., Fonteyne, V., Claeys, T., De Vos, F., Huysse, W., Hautekiet, A., Maes, G., & Ost, P.
Venue
Radiation Oncology
Published
2014-06-12
Volume
9
Issue
1
Pages
135-135
ISSN
1748-717X (ISSN-L)
OpenAlex
W2127240958
Cited by
255
References
26
FWCI
17.93
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. https://app.cochat.ai/papers/10.1186/1748-717x-9-135
The paper
Decaestecker, K., De Meerleer, G., Lambert, B., Delrue, L., Fonteyne, V., Claeys, T., De Vos, F., Huysse, W., Hautekiet, A., Maes, G., & Ost, P. (2014). Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiation Oncology. https://doi.org/10.1186/1748-717x-9-135

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.